SAB Biotherapeutics
SABS
24 hedge funds and large institutions have $15.2M invested in SAB Biotherapeutics in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 21 closing their positions.
32.32% more ownership
Funds ownership: 3.86% → 36.18% (+32%)
38% less capital invested
Capital invested by funds: $24.5M → $15.2M (-$9.33M)
43% less funds holding
Funds holding: 42 → 24 (-18)
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
86% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$422K |
| 2 |
Millennium Management
New York
|
+$298K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$153K |
| 4 |
BlackRock
New York
|
+$5.92K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$3.52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.63M |
| 2 |
FPB
First PREMIER Bank
Sioux Falls,
South Dakota
|
-$555K |
| 3 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$60.5K |
| 4 |
State Street
Boston,
Massachusetts
|
-$55.9K |
| 5 |
Mariner
Overland Park,
Kansas
|
-$47.4K |
SABS Hedge Fund Activity: Q1 2024 in Review
24 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q1 2024, worth a combined $15.2M — down 38% from $24.5M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of SABS and 3 opened new positions — a net loss of 18 holders — while 12 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $422K. The largest seller was RA Capital Management, exiting entirely with an estimated $1.63M sold.
- 24 institutional investors held SAB Biotherapeutics (SABS) as of Q1 2024, down from 42 in Q4 2023.
- Funds reported $15.2M of SAB Biotherapeutics stock for Q1 2024, down 38% quarter-over-quarter.
- 3 funds opened new SAB Biotherapeutics positions in Q1 2024 and 21 closed out, a net change of -18 holders.
- The largest SAB Biotherapeutics buyer in Q1 2024 was Vanguard Group, an estimated $422K added.
- The largest SAB Biotherapeutics seller in Q1 2024 was RA Capital Management, an estimated $1.63M sold.
Based on aggregated 13F filings for Q1 2024.